These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21402801)

  • 1. Clopidogrel: to test or not to test? That is the question--still.
    Cannon CP
    Clin Chem; 2011 May; 57(5):659-61. PubMed ID: 21402801
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
    Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
    [No Abstract]   [Full Text] [Related]  

  • 3. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 4. Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.
    Roden DM; Shuldiner AR
    Circulation; 2010 Aug; 122(5):445-8. PubMed ID: 20585014
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 7. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
    Smock KJ; Saunders PJ; Rodgers GM; Johari V
    Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 9. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 10. Clopidogrel poor metabolizers may need alternative to standard regimen.
    Thompson CA
    Am J Health Syst Pharm; 2010 May; 67(10):779-80. PubMed ID: 20479095
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 14. Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel.
    Osnabrugge RL; Kappetein AP; Janssens AC
    JAMA; 2011 Feb; 305(5):467-8; author reply 468. PubMed ID: 21285422
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
    Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR;
    Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
    Fuster V; Sweeny JM
    JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263
    [No Abstract]   [Full Text] [Related]  

  • 17. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 18. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study.
    Prüller F; Drexler C; Archan S; Macher S; Raggam RB; Mahla E
    J Thromb Haemost; 2011 Aug; 9(8):1670-3. PubMed ID: 21649849
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical-scientific notes.
    Dick RJ; Byron KA; Dear AE
    Intern Med J; 2012 Oct; 42 Suppl 5():7-8. PubMed ID: 23035675
    [No Abstract]   [Full Text] [Related]  

  • 20. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.